Crossmark

Kidney transplantation for treatment of end-stage kidney disease after haematopoietic stem cell transplantation: case series and literature review

Crossref DOI link: https://doi.org/10.1007/s10157-018-1672-1

Published Online: 2018-12-24

Published Print: 2019-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

,

Tsuchimoto, Akihiro

Masutani, Kosuke

Omoto, Kazuya

Okumi, Masayoshi

Okabe, Yasuhiro

Nishiki, Takehiro

Ota, Morihito

Nakano, Toshiaki

Tsuruya, Kazuhiko

Kitazono, Takanari

Nakamura, Masafumi

Ishida, Hideki

Tanabe, Kazunari
Funding

Funding for this research was provided by:

Astellas Pharma
License Information

Text and Data Mining valid from 2018-12-24
More Information

Article History

Received: 8 June 2018

Accepted: 13 November 2018

First Online: 24 December 2018

Compliance with ethical standards

:

: Potential financial conflicts of interest: Astellas Pharma Inc. (Tokyo, Japan) supported this study and Kazunari Tanabe with a grant. The sponsor was not involved in the study design, patient enrolment, data collection, analysis, interpretation, or preparation of the manuscript.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee at which the studies were conducted (IRB approval number UMIN000018327) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: Written informed consent was obtained from all individual participants included in the study.